news
US enters agreement for experimental prophylactic COVID-19 antibody cocktail
The US government will develop and manufacture AstraZeneca’s investigational monoclonal antibody cocktail, AZD7442, a potential prophylactic treatment for COVID-19.
List view / Grid view
Drug Manufacturing
article
Who will receive COVID-19 vaccines first?
EPR’s Hannah Balfour discusses some of the proposed COVID-19 vaccine distribution plans and how medicinal nationalism and supply deals could prevent “fair and equitable access” to COVID-19 vaccines.
news
J&J to supply Europe with 200 million doses of COVID-19 vaccine
J&J has agreed that it will supply the EU with 200 million doses of its COVID-19 vaccine candidate following regulatory approval.
article
How can virtual pharma companies de-risk new product launches?
Christoph Krähenbühl outlines five considerations for virtual pharmaceutical companies when launching a new drug product.
news
Majority of CMO-acquired dose manufacturing facilities in Europe, report says
A new report has found that three quarters of dose manufacturing facilities acquired by dedicated CMOs in 2019 were in Europe.
news
CDMO to conduct fill and finish manufacture of COVID-19 vaccine
US outsourcing organisation GRAM is set to undertake the aseptic fill and finish manufacture of J&J's COVID-19 vaccine candidate.
news
Global HPAPI market to grow at CAGR of 8.7 percent by 2026
A report has said that the highly potent compound market will grow to be worth $32,200 million by the end of 2026.
news
Novavax begins Phase III COVID-19 vaccine efficacy trial
The trial will evaluate the safety and efficacy of the Novavax’ NVX-CoV2373 vaccine candidate in approximately 10,000 UK participants.
news
UK and EU pharma call for medicines to be prioritised in Brexit trade talks
The ABPI and EFPIA have both emphasised the need for trade talks to mitigate medicine supply chain disruptions following Brexit.
news
Importance of sublimation tests when freeze-drying HPAPIs shown in study
Researchers have shown that sublimation tests should be conducted if new components are added to the freeze-drying process of HPAPIs.
news
Research finds 25 percent of drugs contain highly potent compounds
A new report has said that a quarter of drugs globally are based on highly potent active pharmaceutical ingredients.
news
Serum Institute of India: outsourced manufacturing of COVID-19 vaccines
As the COVID-19 pandemic and the search for an effective preventative vaccine continues, the Serum Institute of India has entered into manufacturing agreements with both Novavax and Codagenix to help supply their experimental COVID-19 vaccine candidates.
news
Outsourcing facility opens highly potent compound manufacturing suite
The development of a highly potent active pharmaceutical ingredient (HPAPI) contract manufacturing facility has been completed in the US.
news
UK Prime Minister visits the UK Vaccines Manufacturing and Innovation Centre (VMIC)
Prime Minister Boris Johnson visited the construction site of the VMIC and met scientists and engineers at the forefront of the UK’s COVID-19 response.
news
An overview of Indian COVID-19 vaccine supply and development
Prashant Khadayate, Pharma Analyst at GlobalData, explains what the current state of the COVID-19 pandemic is in India and what vaccine options are currently under development/testing.
